simotinib

Simotinib is a small molecule, orally bioavailable, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It was developed as an antineoplastic agent for the treatment of cancers with EGFR mutations, particularly non-small cell lung cancer (NSCLC). Simotinib inhibits EGFR by binding to its tyrosine kinase domain and blocking downstream signaling pathways involved in tumor cell proliferation and survival. Clinical studies have shown that simotinib is well tolerated at doses up to 650 mg twice daily, with rash and diarrhea being the most common adverse events. The drug has demonstrated partial responses and stable disease in patients with advanced NSCLC harboring EGFR mutations, including those with brain metastases[2][3][7][10].

Brand names

simotinib

Other names

UNII-58K797D5IKUNII58K797D5IKUNII 58K797D5IKXimotiniSimotinib hydrochloride